The Food and Drug Administration on Monday approved a once-daily pill for sickle cell disease that works in an entirely new way — by boosting hemoglobin, the oxygen-carrying molecule found in red blood cells.

The novel drug was developed by the biotech firm Global Blood Therapeutics (GBT) and will be sold under the brand name Oxbryta. The drug’s approval came three months earlier than expected.

Unlock this article by subscribing to STAT Plus. To get you started, enjoy 50% off your first 3 months!

GET STARTED

What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Leave a Comment

Please enter your name.
Please enter a comment.

  • Thank you for keeping us inform, how can we get for the Dominican Republic?
    Warm Regards,
    Angela Mercado
    MPH 2020
    Monroe College

  • I have a sickle child 9 years she is now on hydroxcurea 500mg daily. How long will take the medicine? Is there anything to cure the disease? For now i am giving her dates and milk juice daily and her Haemoglobin is 11.5

  • If it really does make oxygen bind more tightly to hemoglobin, it sounds like just what is needed (in combination with inhaled oxygen) for immediate treatment of carbon monoxide poisoning in the general population. Something like an epi-pen, but with this drug instead.

    • I think that is very unlikely that a solid oral dose would be used for that acute situation. I have not read any information about this drugs PK profile but I think it much more likely it works over the course of weeks.

Your daily dose of news in health and medicine

Privacy Policy